News | Pacemakers | June 16, 2020

Biotronik Launches His-Bundle Pacing Tools

His pacing allow physicians more choices in achieving physiological pacing

Biotronik Launchs His-Bundle Pacing Tools

June 16, 2020 - Biotronik has today announced its commitment to giving physicians additional tools to pace in the His-Bundle, coinciding with the launch of its His-Bundle Pacing (HBP) tools in a limited number of centers starting now with a full launch later in 2020.

The gradual launch will help ensure physicians who are adopting Biotronik's tools have the adequate training opportunity during implantation.

Biotronik has an ongoing commitment to collaborating with electrophysiology (EP) physicians to help improve the lives of patients across the globe. An advisory board including HBP pioneers from over 13 countries have been working closely with Biotronik's developers to advise on optimal catheter design solutions for gaining smoother access to the tricky bundle of His.

Inconsistent procedure success remains a key concern for physicians when considering HBP implantation. Biotronik wants to help overcome this challenge and provide physicians with alternative tools they can rely on during clinical procedures.

"Achieving a pacing strategy that closely resembles intrinsic rhythm is well known to guarantee a superior clinical outcome," said Francesco Zanon, M.D., from Santa Maria della Misericordia in Rovigo, Italy. "But having the right tools has been one of the most important factors during HBP implantation."

There is a continued search for alternative pacing sites, and naturally, more flexible tools that may assist access to these sites. Pacing via the His Bundle uses the natural conduction system and therefore shows a normal QRS duration.

Studies have shown that long-term right ventricular pacing can result in a high incidence of myocardial perfusion defects that may increase with the duration of pacing.[1] Long-term right ventricular pacing is also associated with higher rates of atrial fibrillation, heart failure and mortality.[2-4]

"In the His-Bundle Pacing project we involved physicians from day one, co-creating product designs and receiving constant feedback to offer the tools our physician need to unlock higher rates of success," said Volker Lang, Biotronik senior vice president research and development CRM. "We are translating our proven product quality into innovations that help improve outcomes in the operating room."

Read about His-bundle pacing in the late-breaking Heart Rhythm Society 2020 meeting study Left Bundle Branch Pacing is Feasible as a Novel Strategy For Cardiac Resynchronization Therapy.

This technology is also iscussed in the VIDEO: Top New EP Technologies at Heart Rhythm Society 2020 — Interview with Andrew Krahn, M.D.

References: 

1. Tse, Hung-Fat; Lau, Chu-Pak (1997): Long-Term Effect of Right Ventricular Pacing on Myocardial Perfusion and Function. In Journal of the American College of Cardiology 29 (4), pp. 744–749. DOI: 10.1016/S0735-1097(96)00586-4.

2. Sweeney, Michael O.; Hellkamp, Anne S.; Ellenbogen, Kenneth A.; Greenspon, Arnold J.; Freedman, Roger A.; Lee, Kerry L.; Lamas, Gervasio A. (2003): Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. In Circulation 107 (23), pp. 2932–2937. DOI: 10.1161/01.CIR.0000072769.17295.B1.

3. Wilkoff, Bruce L.; Cook, James R.; Epstein, Andrew E.; Greene, H. Leon; Hallstrom, Alfred P.; Hsia, Henry et al. (2002): Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator. The Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. In JAMA 288 (24), pp. 3115–3123. DOI: 10.1001/jama.288.24.3115.

4. Nielsen, Jens C.; Kristensen, Lene; Andersen, Henning R.; Mortensen, Peter T.; Pedersen, Ole L.; Pedersen, Anders K. (2003): A randomized comparison of atrial and dual-chamber pacing in177 consecutive patients with sick sinus syndrome. In Journal of the American College of Cardiology 42 (4), pp. 614–623. DOI: 10.1016/S0735-1097(03)00757-5.
 

Related Content

The Stereotaxis Genesis EP robotic navigation system.

The new generation Stereotaxis Genesis EP robotic navigation system.

News | EP Lab | September 01, 2021
September 1, 2021 — Stereotaxis and Shanghai Microport EP Medtech Co., Ltd.
Ventricular Tachycardia Recurrence, Hospitalization and Death Reduced With Catheter Ablation as First Line Therapy. Results from an international clinical trial show a significant reduction in risk of ventricular tachycardia (VT) recurrence, cardiovascular hospitalization, and sudden cardiac death (SCD) death when catheter ablation is used as an early first-line treatment for patients with structural heart disease. Led by study coordinating center, the University of Chicago, The PAUSE-SCD trial. #HRS21
News | EP Lab | August 09, 2021
August 9, 2021 – Results from an international clinical trial show a significant reduction in risk of ventricular tac
Heart Rhythm Society, HRS, 2021 Late-Breaking Clinical Trials in Electrophysiology. #HRS #HRS2021 #HRS21 #Heartrhythm21
Feature | EP Lab | August 09, 2021
July 28, 2021 — Here is the complete list of late-breaking clinical trials (LBCT) and links to articles on all of the
An example from the study of the Biosense Webster NuVision 3D/4D ICE imaging capability showing the left atrial appendage (LAA) visualization on 3D ICE. The system allows the user to place a false lighting source to be placed in different positions to change the lighting and shadows to better visualize the anatomy.

An example from the study of the Biosense Webster NuVision 3D/4D ICE imaging capability showing the left atrial appendage (LAA) visualization on 3D ICE. The system allows the user to place a false lighting source to be placed in different positions to change the lighting and shadows to better visualize the anatomy. 

News | EP Lab | August 05, 2021 | By Dave Fornell, Editor
August 5, 2021 —  A prospective, non-randomized, multicenter, first-in-human clinical study found good diagnostic and
EP lab ablation catheter. #HRS21 #HRS2021
News | EP Lab | August 03, 2021
August 3, 2021 — A subgroup analysis of the EAST – AFNET 4 study population revealed early initiation of rhythm contr
emporary Spinal cord stimulation (SCS) was effective in suppressing post-operative atrial fibrillation (AF) after coronary artery bypass (CAGB) surgery CABG without any adverse events in a randomized pilot study. The TEmporary Spinal CoRd StiMulatIon to PrevenNt Atrial FibrillaTION AFter Cardiac Surgery (TerminationAF) study was presented as a late-breaking study presented at the 2021 Heart Rhythm meeting, the annual conference of the Heart Rhythm Society (HRS).  #HRS21 #HRS2021
News | EP Lab | August 03, 2021
August 4, 2021 — Temporary Spinal cord stimulation (SCS) was effective in suppressing post-operative...
Oral Contraceptives Cause Increased Risk of Cardiac Events in Woman With Long QT Syndrome. #HRS21 #HRS2021 #womenshealth
News | EP Lab | August 03, 2021
August 3, 2021 – Results from a new clinical trial show an increased risk of cardiac events, like sudden cardiac deat
A recent study unveiled a novel sinus node ablation technique that provides a safe and effective treatment option for patients suffering from symptomatic, drug-resistant inappropriate sinus tachycardia (IST). Results of the Susruta-IST Registry were presented as a late-breaking clinical trial at Heart Rhythm 2021, the annual meeting of the Heart Rhythm Society (HRS). #HRS21 #HRS2021

A novel sinus node ablation technique provides a safe and effective treatment option for patients suffering from symptomatic, drug-resistant inappropriate sinus tachycardia (IST). Results of the Susruta-IST Registry were presented as a late-breaking clinical trial at Heart Rhythm 2021.

News | EP Lab | August 03, 2021
August 3, 2021 – A recent study unveiled a novel sinus node...
The Philips EPD Kodex system for the EP lab.
News | EP Lab | August 03, 2021
August 3, 2021 – A new analysis of the Catheter Ablation vs.
The new Octaray high-density mapping catheter from Biosense Webster has 48 electrodes to enable faster and more detailed electromapping of the heart to better guide ablation procedures.

The new Octaray high-density mapping catheter from Biosense Webster has 48 electrodes to enable faster and more detailed electromapping of the heart to better guide ablation procedures. Photo by Dave Fornell

News | EP Lab | August 03, 2021
August 3, 2021 – Biosense Webster, the global leader in cardiac arrhythmia treatment and part of Johnson & Johnso